Litigation Details for Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Docket		Date Filed	2012-03-21
Court	District Court, D. Delaware	Date Terminated	2014-12-08
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	HOSPIRA INC.
Patents	6,468,967; 6,852,689; 8,058,238; 8,129,342
Attorneys	David P. Dalke
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-03-21				External link to document

Cubist Pharmaceuticals v. Hospira, Inc. (1:12-cv-00367): Litigation Summary and Patent Analysis

Last updated: August 25, 2026

Cubist Pharmaceuticals sued Hospira in the U.S. District Court for the District of Delaware after Hospira filed an abbreviated new drug application seeking approval for a generic version of Cubicin, Cubist’s daptomycin injection. The case concerned Orange Book-listed patents covering daptomycin treatment and dosage methods. The litigation produced a significant Federal Circuit decision addressing infringement and validity of Cubist’s daptomycin patent estate. [1][2]

What was Cubist Pharmaceuticals v. Hospira about?

The case was an ANDA patent infringement action under the Hatch-Waxman Act. Hospira’s ANDA filing was treated as a technical act of infringement under 35 U.S.C. § 271(e)(2), based on Hospira’s Paragraph IV allegations against Cubist’s listed patents.

Cubicin contains daptomycin, a cyclic lipopeptide antibiotic used primarily for serious Gram-positive bacterial infections. Cubist marketed Cubicin as an intravenous product for indications including complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis.

The dispute focused on whether Hospira’s proposed generic product and labeling would infringe Cubist patent claims directed to administering daptomycin in specified dosage regimens.

Case identification

Field	Information
Case	Cubist Pharmaceuticals, Inc. v. Hospira, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:12-cv-00367
Filing year	2012
Statutory framework	Hatch-Waxman Act; 35 U.S.C. § 271(e)(2)
Product	Cubicin, daptomycin for injection
Plaintiff	Cubist Pharmaceuticals, Inc.
Defendant	Hospira, Inc.
Principal reported appellate decision	Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 805 F.3d 1112 (Fed. Cir. 2015)
District court citation	75 F. Supp. 3d 641 (D. Del. 2014)

What patents protected Cubicin in the Hospira litigation?

The litigation involved Cubist’s daptomycin patent portfolio, including U.S. Patent No. 6,852,689. The reported Federal Circuit decision centered on the validity and infringement of the ’689 patent. The patent covered methods for treating bacterial infections using daptomycin-based dosage regimens. [1]

Cubist’s broader Cubicin estate included composition, formulation, dosage, and method-of-use patents. Not every Cubicin patent was necessarily litigated to judgment in the Hospira action. The relevant distinction is between patents asserted in the civil action and patents listed in the Orange Book at different points in the product’s commercial life.

Principal patent at issue

Patent	General subject matter	Relevance
U.S. Patent No. 6,852,689	Daptomycin treatment methods and dosage regimens	Principal patent addressed in the reported Hospira appellate litigation

Daptomycin patents generally protected three commercial layers:

1. The active pharmaceutical ingredient and cyclic lipopeptide compounds.
2. Injectable compositions and formulation characteristics.
3. Clinical use, administration frequency, and dosage regimens.

The Hospira litigation was commercially important because method-of-use patents can delay generic approval even after earlier compound or formulation patents expire, provided the patents remain listed and the generic applicant’s proposed labeling induces infringement.

What were Hospira’s Paragraph IV arguments?

Hospira challenged Cubist’s patent rights through a Paragraph IV certification. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product.

The precise theories in this type of litigation generally include:

• Lack of novelty under 35 U.S.C. § 102.
• Obviousness under 35 U.S.C. § 103.
• Lack of written-description support under 35 U.S.C. § 112.
• Lack of enablement.
• Noninfringement based on the proposed product or labeling.
• Failure to establish induced infringement under 35 U.S.C. § 271(b).

Hospira’s challenge placed both validity and infringement at issue. Cubist responded that the claimed daptomycin regimen was supported by the patent specification, was not rendered obvious by the prior art, and would be practiced by patients and healthcare professionals following Hospira’s proposed labeling.

What did the district court decide?

The District of Delaware entered findings adverse to Hospira on the principal patent issues addressed in the reported decisions. The court’s analysis considered the scope of the claimed daptomycin treatment regimen, the prior art, and the relationship between Hospira’s ANDA labeling and the asserted method claims. [1]

The district court’s judgment was reported at 75 F. Supp. 3d 641. The case proceeded to the U.S. Court of Appeals for the Federal Circuit, which issued its decision in 2015. [1][2]

The central legal issue was whether the patent claims were sufficiently supported and whether the prior art made the claimed daptomycin regimen obvious. In ANDA cases, a branded company must establish infringement by showing that the ANDA product, proposed use, or labeling falls within the asserted claims. For method claims, the proposed label can be decisive because it may encourage physicians to administer the drug in the patented manner.

What did the Federal Circuit decide?

In Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 805 F.3d 1112 (Fed. Cir. 2015), the Federal Circuit addressed Cubist’s daptomycin patent claims and upheld the district court’s material conclusions in favor of Cubist. [2]

The appellate ruling confirmed the strength of Cubist’s position on the challenged patent. The decision is relevant for two reasons.

Infringement analysis

The Federal Circuit treated the ANDA and proposed labeling as relevant evidence of intended use. A generic applicant cannot avoid a method-of-use claim merely by characterizing the product as a copy of the active ingredient. If the proposed labeling instructs or encourages administration in a manner covered by the patent, induced infringement may be established.

This principle is especially important for anti-infective products. Dosing schedules, treatment duration, and patient-selection instructions can create infringement exposure even when the generic product has the same active ingredient and dosage form as the reference product.

Validity analysis

The Federal Circuit rejected Hospira’s challenge to the asserted daptomycin patent. The ruling recognized that the claimed regimen was not automatically obvious merely because daptomycin and related dosing information were known in the prior art.

The decision illustrates the importance of clinical unpredictability in pharmaceutical obviousness disputes. Prior-art disclosure of an active ingredient does not necessarily establish that a skilled artisan would have selected the claimed dosage, administration frequency, and treatment regimen with a reasonable expectation of success.

How did the litigation affect generic entry for Cubicin?

The case created a statutory stay of FDA approval under Hatch-Waxman. A timely patent infringement suit following a Paragraph IV notice generally triggers a 30-month stay of approval, subject to court decisions and other statutory exceptions. [3]

For Hospira, the practical result was that FDA approval of its daptomycin ANDA was constrained by the patent litigation and any associated exclusivity period. The litigation did not concern FDA’s scientific determination that daptomycin was safe and effective. It concerned whether Hospira could obtain approval and commercialize its proposed generic product without infringing enforceable Cubist patent claims.

Generic launch scenarios

Scenario	Commercial effect
Cubist wins and obtains an injunction	Hospira’s launch is delayed until patent expiry, settlement permission, or other legal authorization
Hospira prevails on invalidity or noninfringement	FDA approval can proceed after regulatory conditions are satisfied
Settlement with an agreed launch date	Hospira may launch before the latest asserted patent expiry under negotiated terms
Label carve-out accepted by FDA	Generic launch may occur for non-patented uses if the remaining labeling avoids infringement

The reported appellate decision strengthened Cubist’s ability to delay an unlicensed generic launch based on the asserted patent. It did not eliminate the possibility of later entry through patent expiration, settlement, a successful challenge to other patents, or a noninfringing label.

What was the Orange Book status of Cubicin?

Cubicin was approved by the FDA as a daptomycin injection product. The Orange Book listed patents associated with the reference product during the period relevant to generic competition. [4]

Orange Book listing is important because it determines which patents an ANDA applicant must address through Paragraph I, II, III, or IV certifications. A method-of-use patent can remain commercially relevant even when the generic applicant seeks approval for a broader product, because the applicant must address listed use patents and may need to use a carve-out label.

The Orange Book does not determine patent validity. Listing creates the regulatory mechanism for patent certifications and the 30-month stay. Courts determine infringement, validity, and enforceability.

Did the case involve formulation patents?

The Hospira litigation’s principal reported focus was the daptomycin treatment regimen, rather than a standalone formulation dispute. Cubistin’s commercial protection, however, included more than one patent category.

Formulation-related protection may cover:

• Lyophilized daptomycin powder for injection.
• Reconstitution characteristics.
• Stability and storage.
• Excipient selection.
• Concentration and dosage form.
• Manufacturing and fill-finish processes.

A generic applicant can face separate risks from formulation patents even when it defeats a method-of-use patent. Conversely, a formulation patent may be avoided through a different manufacturing process or excipient system if the resulting product does not fall within the asserted claims.

How strong was Cubist’s patent estate?

Cubist’s patent estate was strong in the Hospira case because it combined statutory exclusivity with multiple patent categories and a clinically specific method-of-use position.

Strengths

• The asserted patent survived a validity challenge.
• The Federal Circuit affirmed the principal district court outcome.
• The claims were tied to a specific clinical dosing regimen.
• Hospira’s proposed labeling supplied evidence relevant to induced infringement.
• The Hatch-Waxman framework created a regulatory stay after the Paragraph IV challenge.

Limitations

• Method-of-use patents depend heavily on the proposed label.
• Physician behavior may be difficult to prove outside the ANDA context.
• Patent protection was finite and subject to Orange Book expiration dates.
• Generic applicants could pursue label carve-outs.
• Separate patents required separate infringement and validity analyses.

Cubist’s estate therefore had meaningful near-term blocking power but did not create permanent protection for daptomycin.

Which companies challenged Cubicin exclusivity?

Hospira was one of the major ANDA challengers involved in litigation over generic daptomycin. Other generic manufacturers also pursued daptomycin products as the relevant patents and regulatory exclusivities expired or were narrowed.

The competitive landscape included companies capable of entering through:

• Paragraph IV litigation.
• Paragraph III certifications tied to patent expiry.
• Section viii statements and use-specific carve-outs.
• Licensing or settlement agreements.
• FDA approval after the 30-month stay expired.

The strength of a generic challenge depended on the particular patent claim, not simply on whether the applicant had an ANDA for the same active ingredient.

Did Cubist and Hospira enter a settlement agreement?

The reported appellate decision establishes the litigation outcome addressed by the courts. A publicly documented settlement agreement is not the same as a judicial finding and should not be inferred from later generic availability.

No settlement term should be treated as controlling unless it appears in a filed agreement, Federal Trade Commission review material, SEC filing, or court order. The relevant public litigation record for this action is the District of Delaware docket and the reported district and Federal Circuit opinions. [1][2]

What was the commercial significance for Cubicin revenue?

Cubicin was a major Cubist product and a substantial source of company revenue before generic daptomycin competition. Patent litigation affected the timing of generic entry, which directly influenced the duration of branded pricing and market share.

Revenue exposure depended on:

• Cubicin annual sales before generic entry.
• The number of approved generic suppliers.
• The timing of first commercial launch.
• Whether generic entrants obtained 180-day shared or sole first-filer exclusivity.
• The extent of physician switching.
• Hospital purchasing contracts.
• The number of remaining patented uses.

The litigation’s commercial value was therefore measured by delayed generic penetration, not only by any damages award.

What litigation lessons apply to other pharmaceutical ANDA cases?

The case demonstrates four recurring principles.

First, an ANDA dispute can turn on proposed labeling rather than chemical identity. Second, a dosing regimen may remain patentable even when the active ingredient is old. Third, clinical unpredictability can support nonobviousness where the prior art does not establish a reasonable expectation of success. Fourth, an appellate affirmance can increase settlement leverage by reducing the generic applicant’s probability of an immediate launch.

Key Takeaways

• Cubist sued Hospira in Delaware over a proposed generic version of Cubicin, daptomycin for injection.
• The case was an ANDA Paragraph IV action under 35 U.S.C. § 271(e)(2).
• U.S. Patent No. 6,852,689 was the principal patent addressed in the reported appellate litigation.
• The dispute centered on daptomycin treatment and dosage-regimen claims.
• The district court ruled in Cubist’s favor on the principal issues, and the Federal Circuit affirmed the material outcome in 2015.
• The case reinforced the importance of proposed generic labeling in induced-infringement analysis.
• Cubist’s protection included method-of-use rights in addition to formulation and other daptomycin-related patents.
• Generic entry remained dependent on patent expiry, regulatory stays, settlements, label carve-outs, and outcomes in other Cubicin patent proceedings.

FAQs

What drug was at issue in Cubist v. Hospira?

The drug was daptomycin, marketed by Cubist as Cubicin for intravenous treatment of serious Gram-positive bacterial infections.

Was Cubist v. Hospira a biosimilar case?

No. It was a small-molecule ANDA case involving a generic daptomycin product, not a biologics license application or biosimilar application under the Public Health Service Act.

Did Hospira challenge the active ingredient or the dosing method?

The reported litigation focused principally on patent claims covering daptomycin treatment and dosage regimens. The legal issues included both infringement and validity.

Can a generic daptomycin product avoid infringement through a label carve-out?

Potentially. A Section viii statement and FDA-accepted use carve-out can reduce method-of-use risk, but the result depends on the specific patent claims, label language, and evidence of induced infringement.

What is the leading citation for the Cubist-Hospira appeal?

The leading Federal Circuit citation is Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 805 F.3d 1112 (Fed. Cir. 2015).

References

1. Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 75 F. Supp. 3d 641 (D. Del. 2014).

2. Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 805 F.3d 1112 (Fed. Cir. 2015).

3. 21 U.S.C. § 355(j)(5)(B)(iii).

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.